Wanbury Limited
Incorporated in 1988, Wanbury Ltd is in the business of pharmaceutical and related activities, including research
What Wanbury files
- Others58
- Updates34
- Board Meeting18
- Important7
- Insider Trade5
- PPTs5
Wanbury Limited has informed the Exchange about Copy of Newspaper Publication: Information regarding 38th Annual General Meeting to be held through Video Conferencing (VC)/Other Audio Visual Means (OAVM).
Wanbury Limited has announced a book closure from September 18, 2026, to September 24, 2026, (inclusive). This period is set for its 38th Annual General Meeting, scheduled for September 24, 2026. Shareholders registered on September 17, 2026, will be eligible to participate and vote at the AGM.
Wanbury Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 24, 2026
Wanbury Limited has informed the Exchange about Copy of Newspaper Publication
Wanbury secured EDQM approval for Rivaroxaban API, boosting EU market access. The company also received USFDA DMF clearances for Paraxetine HCl and Metformin HCl, strengthening its product pipeline and reach for customers.